GMI 1271

Drug Profile

GMI 1271

Alternative Names: GMI-1271

Latest Information Update: 08 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlycoMimetics
  • Class Antineoplastics; Antithrombotics; Glycolipids; Small molecules
  • Mechanism of Action E-selectin inhibitors; P-selectin ligand protein inhibitors; Protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia
  • Phase I/II Deep vein thrombosis
  • Phase I Multiple myeloma; Stem cell mobilisation
  • Preclinical Chronic myeloid leukaemia; Solid tumours

Most Recent Events

  • 08 Nov 2017 GlycoMimetics plans a phase III trial for Acute myeloid leukaemia (Second-line therapy) in mid-2018
  • 06 Jul 2017 GlycoMimetics receives Intention to Grant letter for a patent for GMI 1271 in Europe
  • 05 Jun 2017 Updated adverse events and efficacy data from a phase II portion of the phase I/II trial in Acute myeloid leukaemia presented at the Annual Meeting of American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top